Merck & Co., Inc. said WINREVAIR (sotatercept-csrk) met the primary endpoint in the Phase 2 CADENCE trial in adults with combined post- and precapillary pulmonary hypertension and heart failure with preserved ejection fraction, or CpcPH-HFpEF, showing a statistically significant reduction in pulmonary vascular resistance versus placebo at week 24. The result gives the U.S.-based drugmaker proof-of-concept in a patient population with no approved therapies specifically indicated for the condition and sets up discussions with regulators on a registrational Phase 3 study.

Why Merck’s CADENCE trial matters for WINREVAIR beyond its existing pulmonary arterial hypertension use

What makes the readout notable is not simply that a primary endpoint was met, but that Merck is trying to stretch WINREVAIR beyond its already established pulmonary arterial hypertension franchise into a more complex and commercially less straightforward cardiovascular setting. CpcPH-HFpEF sits at the intersection of pulmonary vascular dysfunction and cardiac disease, which immediately makes development harder. Unlike pulmonary arterial hypertension, where trial frameworks and endpoints are relatively mature, this population is older, more comorbid, and clinically messier. That means even a positive Phase 2 result does not automatically translate into a clean regulatory or commercial path.

What is genuinely new in WINREVAIR’s Phase 2 CpcPH-HFpEF data and what still looks incremental

The genuine novelty in CADENCE is that sotatercept appears to have shown hemodynamic activity in a subgroup that has long resisted clear therapeutic progress. The primary endpoint was change in pulmonary vascular resistance, and both tested doses beat placebo numerically, with the 0.3 mg/kg arm showing the sharper result. That matters because it suggests the drug’s mechanism may have relevance beyond classic Group 1 pulmonary arterial hypertension. Industry observers tracking pulmonary hypertension have long viewed left-heart-associated pulmonary hypertension as an area littered with biological complexity and repeated disappointment. Against that backdrop, any credible signal tied to invasive hemodynamics draws attention.

Still, the trial also shows why enthusiasm will need to stay disciplined. CADENCE was a proof-of-concept Phase 2 study, not a registrational program built to settle clinical practice. Its strongest evidence lies in hemodynamic improvement, while some of the more intuitively meaningful clinical measures remain less definitive. The 0.7 mg/kg arm improved six-minute walk distance by 5.8 meters without statistical significance, while the 0.3 mg/kg arm showed a 20.3-meter gain but without formal secondary endpoint testing because of the hierarchical design. That creates a familiar development problem. The biology may be pointing in the right direction, but the clinical story is not yet fully locked down in the way payers, regulators, and heart failure specialists usually want.

Why WINREVAIR dose selection in CADENCE could become a key issue for Phase 3 design

That dose split is one of the most interesting features of the readout. Merck is effectively signaling that the lower 0.3 mg/kg dose may offer the better benefit-risk profile in this population. In drug development terms, that is not a weakness by itself. Lower-dose efficacy can be attractive in fragile patient groups, especially older patients with multiple comorbidities. But it does raise questions about therapeutic consistency and about how confidently the program can define its optimal regimen before Phase 3. Regulatory watchers often look closely at whether dose selection is being driven by a clearly interpretable exposure-response relationship or by a more pragmatic attempt to balance mixed efficacy and safety signals.

What the CADENCE safety profile suggests about tolerability risks in an older heart failure population

The safety profile also deserves a measured read. Merck said the overall profile was generally consistent with prior WINREVAIR experience, which helps because it reduces the risk of a completely new toxicity narrative emerging in this new population. But CADENCE still hints at tolerability friction, particularly in the 0.7 mg/kg arm, where serious adverse events and discontinuations were higher than in the 0.3 mg/kg arm and placebo. In a rare and high-risk disease setting, manageable safety may be acceptable if the clinical benefit is strong enough. The issue is that the benefit case here still rests more on directionally supportive evidence than on a clearly practice-changing functional outcome package.

Why diagnosing and treating CpcPH-HFpEF could limit real-world uptake even if Phase 3 succeeds

That distinction matters because CpcPH-HFpEF is not just underserved. It is diagnostically and operationally difficult. Many patients are older, often with atrial fibrillation, diabetes, and advanced heart failure features, exactly the kind of profile that complicates trial enrollment, specialist referral, and real-world uptake. Even if WINREVAIR advances into Phase 3 successfully, adoption would likely depend on whether clinicians can reliably identify the right phenotype and whether healthcare systems can support the invasive hemodynamic workup often needed to characterize these patients. A therapy can be mechanistically elegant and still commercially constrained if the target population remains hard to find and harder to manage.

Which clinical endpoints Merck may need to prove for WINREVAIR to win regulatory and payer support

There is also the question of endpoint translation. Pulmonary vascular resistance is meaningful, especially in mechanistic and early-stage studies, but Phase 3 success will probably require endpoints that are more obviously relevant to clinicians, regulators, and reimbursement decision-makers. Merck has already indicated it is working with regulators on outcomes most relevant to this population. That language suggests the company understands Phase 2 alone will not be enough. Future studies may need to show a convincing effect on clinical worsening, hospitalization burden, exercise function, symptom burden, or some composite that captures how these patients actually fare over time. Without that, the program risks being seen as scientifically interesting but clinically incomplete.

How CADENCE could influence the long-term commercial strategy for Merck’s WINREVAIR franchise

Another reason the CADENCE result matters is strategic. WINREVAIR is already one of Merck’s more closely watched cardiovascular and pulmonary assets following its approval in pulmonary arterial hypertension. Expanding into adjacent pulmonary vascular diseases could materially widen the product’s long-term value. But expansion attempts often expose whether a first-in-class success is platform-like or indication-specific. CADENCE improves the argument that activin signaling modulation may have broader disease relevance. At the same time, it does not yet prove that the WINREVAIR story can replicate itself across disease categories with equal force.

What clinicians and regulators are likely to watch next as WINREVAIR moves toward registrational testing

Clinicians tracking the field will also be watching whether the CpcPH-HFpEF population behaves as a distinct therapeutic segment or whether broader HFpEF complexity dilutes drug effect in larger studies. That has been a recurring issue across heart failure research. Subgroups can look biologically coherent in smaller studies but become harder to isolate once Phase 3 broadens the lens. Merck’s challenge will be to preserve the sharpness of the signal without designing a study so narrow that it becomes operationally difficult or commercially limiting.

From a competitive standpoint, the absence of approved therapies specifically for CpcPH-HFpEF is both an opportunity and a warning sign. The white space is real, but so is the history of failed or inconclusive attempts to intervene in pulmonary hypertension linked to left heart disease. That means Merck is not stepping into a validated market; it is trying to build one. In such settings, regulators can be exacting, physicians can be cautious, and payers can demand unusually strong evidence before broad acceptance follows. The company therefore needs more than a positive proof-of-concept headline. It needs a Phase 3 design that turns biological plausibility into undeniable clinical relevance.

Why the next WINREVAIR study matters more than the headline from CADENCE itself

The CADENCE readout ultimately looks like a meaningful but still early inflection point for WINREVAIR. Merck has shown enough to justify continued development and enough consistency across hemodynamic, echocardiographic, biomarker, and clinical trend lines to keep the program credible. But the trial does not eliminate the central uncertainties around dose selection, endpoint hierarchy, clinical meaningfulness, and real-world scalability in an elderly, comorbidity-heavy population. In other words, CADENCE makes the next step possible, not inevitable.

The significance lies in what CADENCE now makes possible rather than in the headline alone. The Phase 2 result suggests Merck may have identified a credible expansion path for WINREVAIR into a difficult and underserved cardiopulmonary setting, but the real test will come in Phase 3, where proof-of-concept must translate into clinically convincing and commercially workable evidence.

  CADENCE trial, cardiometabolic disease, CpcPH-HFpEF, heart failure with preserved ejection fraction, Inc., Merck & Co., pulmonary hypertension, pulmonary vascular resistance, sotatercept-csrk, WINREVAIR